Navigation Links
Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
Date:2/10/2010

tion">the United States, and bipolar disorder, which affects approximately 5.7 million adults in the United States.  More than 90% of these patients will experience agitation in their lifetime.

Agitation generally escalates over time with patients initially feeling uncomfortable, tense and restless.  As the agitation intensifies, their behavior appears more noticeable to others as they become threatening and potentially violent, especially if the agitation is not treated.  While patients seek treatment at different points along this agitation continuum, those with the most severe symptoms generally require treatment with injectable drugs in emergency medical settings, and currently are thought to represent the agitation market.  Alexza, however, believes the therapeutic market for agitation is broader than only this limited perspective of patients in severe crisis — many more are in need of treatment for an agitation episode.

Alexza's primary market research indicates that approximately 50% of treated acute agitation episodes are treated in emergency settings.  Another approximately 35% of the treated agitation episodes suffered by schizophrenic and bipolar patients are treated in an inpatient setting (hospital and long-term residential settings), and approximately 15% are treated in a physician's office.

Alexza's market research studies with schizophrenia patient caregivers and bipolar patients indicate these patients currently experience an average of 11 to 12 episodes of acute agitation each year.

Agitation episodes are currently treated about 55% of the time with oral antipsychotics and about 45% of the time with intra-muscular, or IM, injections.  Oral medications work relatively slowly, but are easy to administer, painless and are less threatening to patients.  IM injections have a faster onset of action and a higher predictabili
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009
2. A Random Act of Kindness Changes a Familys Life Forever as Alexzander Prados Wish to Walk is Granted at Abilities Expo
3. Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002
4. Alexzas Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
5. Alexzas Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference
6. Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
7. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
8. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
9. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
10. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
11. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Plains, NJ (PRWEB) , ... August 31, 2015 ... ... practice! Garden State Urology was formed in 2008, the result of a merger ... the principle that by working cooperatively, they could provide more cost-effective and higher ...
(Date:8/31/2015)... NJ (PRWEB) , ... August 31, 2015 , ... NJ Top Docs Presents, Dr. Michael ... and raised in Park Ridge, New Jersey, Dr. Michael Betsy graduated from Don Bosco Prep ... hockey and served as team captain in both sports in his senior year. He ...
(Date:8/31/2015)... ... ... Dr. Stewart Shofner of Shofner Vision Center explains what causes lazy ... eye examination can diagnose amblyopia. According to the National Eye Institute (NEI), ... to 3 out of every 100 children. , Dr. Shofner adds, “unless amblyopia ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... marketing communications company announced today that it has officially launched a new website ... new website and brand refresh are more closely aligned with the company’s strategic ...
(Date:8/31/2015)... ... August 31, 2015 , ... Three Bakers Gluten Free ... retailers with even more relevant and easy-to-find information on their offering of gluten-free breads ... has always been an important way for us to share information about our gluten ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2
... , WEDNESDAY, Dec. 8 (HealthDay News) -- ... of developing several invasive bacterial diseases, according to a ... found to be especially strong for children 6 years ... the risk for invasive meningococcal disease, the analysis found, ...
... 8, 2010) Jeffrey S. Upperman, MD, director of ... a call to action for filling a significant gap in ... the framework for a pediatric applied trauma research network (PATRN). ... Journal of Pediatric Surgery and the Journal ...
... breakthrough? See what the experts have to say ... Perspectives on Psychological Science . Neuroimaging: ... Special Section on fMRI ( http://pps.sagepub.com/content/5/6/714.full ) ... widespread interest following the publication of Vul et ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- The children ... pregnancy are less likely to develop atopic dermatitis in their ... Atopic dermatitis (also called atopic eczema) is a chronic and ... The condition affects up to 20 percent of children in ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- A new ... blood to scan the genome of a fetus may offer ... genetic diseases, a new study suggests. Currently, a sample ... amniocentesis or chorionic villus sampling, both of which pose a ...
... ANN ARBOR, Mich. Patients who have complications after ... even when it is clearly recommended for their diagnosis, ... Cancer Center finds. In addition, patients with complications ... chemotherapy delayed for more than 120 days after diagnosis ...
Cached Medicine News:Health News:Trauma surgeon leads call to action for pediatric applied trauma research network 2Health News:fMRI special section of Perspectives on Psychological Science 2Health News:fMRI special section of Perspectives on Psychological Science 3Health News:Surgery complications linked to chemotherapy delay, U-M study finds 2
(Date:8/31/2015)... PARK, Calif. , Aug. 31, 2015 /PRNewswire/ ... company focused on the emerging field of regenerative ... successfully dosed at Chicago -based ... clinical trial evaluating activity of escalating doses of ... with sensory and motor complete cervical spinal cord ...
(Date:8/31/2015)... Vascular Ltd., together with its subsidiaries (the "Company" ... the "Group"), a global company engaged in the ... for the minimally invasive treatment of vascular disease, ... ("BTK") cohort of patients in the Chocolate® Balloon ... 15, 2015 at the 5th Annual Amputation Prevention ...
(Date:8/31/2015)... , Aug. 31, 2015 Research ... addition of the "Prescription Pain Drugs - ... Marijuana - Global Markets, Competitors and Opportunities: 2015 ... their offering. Pain is defined ... with actual or potential tissue damage. At some ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... HARBIN, China , May 18 /PRNewswire-Asia-FirstCall/ -- ... (Nasdaq: CSKI ), a leading fully,integrated pharmaceutical company producing ... today announced record financial results,for the first quarter of 2010. ... Form 10-K for 2009. , , First ...
... HARBIN, China , May 18 ... Board: WKBT) ("Weikang" or the,"Company"), a leading developer, manufacturer ... and other health,and nutritional products in the People,s ... the first quarter of fiscal year 2010 ended on ...
Cached Medicine Technology:China Sky One Medical Announces First Quarter 2010 Results 2China Sky One Medical Announces First Quarter 2010 Results 3China Sky One Medical Announces First Quarter 2010 Results 4China Sky One Medical Announces First Quarter 2010 Results 5China Sky One Medical Announces First Quarter 2010 Results 6China Sky One Medical Announces First Quarter 2010 Results 7China Sky One Medical Announces First Quarter 2010 Results 8China Sky One Medical Announces First Quarter 2010 Results 9China Sky One Medical Announces First Quarter 2010 Results 10China Sky One Medical Announces First Quarter 2010 Results 11China Sky One Medical Announces First Quarter 2010 Results 12China Sky One Medical Announces First Quarter 2010 Results 13China Sky One Medical Announces First Quarter 2010 Results 14Weikang Bio-Technology Reports First Quarter 2010 Financial Results 2Weikang Bio-Technology Reports First Quarter 2010 Financial Results 3Weikang Bio-Technology Reports First Quarter 2010 Financial Results 4Weikang Bio-Technology Reports First Quarter 2010 Financial Results 5Weikang Bio-Technology Reports First Quarter 2010 Financial Results 6Weikang Bio-Technology Reports First Quarter 2010 Financial Results 7Weikang Bio-Technology Reports First Quarter 2010 Financial Results 8Weikang Bio-Technology Reports First Quarter 2010 Financial Results 9Weikang Bio-Technology Reports First Quarter 2010 Financial Results 10Weikang Bio-Technology Reports First Quarter 2010 Financial Results 11
... monitor elevates bedside glucose testing to a ... the quality of central laboratory testing. ... strip technology. Current glucose strips use ... system measures and corrects hematocrit interference as ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... BreatheX is a wearable CPAP (Continuous Positive ... sleep apnea. The lightweight BreatheX CPAP device ... with its built-in, rechargeable battery, and is ... no longer need to be "plugged in ...
Paraffin Block Storage System...
Medicine Products: